RGNX

Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome

Regenxbio stock surges on director share purchases

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity (NASDAQ:RGNX)

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street

Why Did RGNX Stock Crash Today?

REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121